Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1948 2
1951 1
1954 1
1956 1
1957 1
1958 1
1959 1
1960 2
1961 1
1962 2
1964 1
1965 1
1966 1
1967 2
1968 1
1969 1
1970 7
1971 8
1972 13
1973 7
1974 9
1975 8
1976 15
1977 10
1978 4
1979 4
1980 4
1981 8
1982 2
1983 4
1984 6
1985 5
1986 7
1987 10
1988 7
1989 11
1990 3
1991 8
1992 7
1993 7
1994 8
1995 5
1996 17
1997 18
1998 9
1999 4
2000 8
2001 6
2002 13
2003 6
2004 8
2005 12
2006 18
2007 8
2008 12
2009 15
2010 5
2011 18
2012 18
2013 16
2014 14
2015 18
2016 26
2017 11
2018 17
2019 17
2020 19
2021 12
2022 9
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

539 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Mosgaard BJ, Selle F, Guyon F, Pomel C, Lécuru F, Zang R, Avall-Lundqvist E, Kim JW, Ponce J, Raspagliesi F, Kristensen G, Classe JM, Hillemanns P, Jensen P, Hasenburg A, Ghaem-Maghami S, Mirza MR, Lund B, Reinthaller A, Santaballa A, Olaitan A, Hilpert F, du Bois A; DESKTOP III Investigators. Harter P, et al. Among authors: meier w. N Engl J Med. 2021 Dec 2;385(23):2123-2131. doi: 10.1056/NEJMoa2103294. N Engl J Med. 2021. PMID: 34874631 Clinical Trial.
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Ledermann J, et al. Among authors: meier w. N Engl J Med. 2012 Apr 12;366(15):1382-92. doi: 10.1056/NEJMoa1105535. Epub 2012 Mar 27. N Engl J Med. 2012. PMID: 22452356 Free article. Clinical Trial.
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.
Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim JW, Raspagliesi F, Lampe B, Aletti G, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum IB, Schmalfeldt B, Burges A, Kimmig R, Scambia G, Greggi S, Hilpert F, Hasenburg A, Hillemanns P, Giorda G, von Leffern I, Schade-Brittinger C, Wagner U, du Bois A. Harter P, et al. Among authors: meier w. N Engl J Med. 2019 Feb 28;380(9):822-832. doi: 10.1056/NEJMoa1808424. N Engl J Med. 2019. PMID: 30811909 Free article. Clinical Trial.
Interfacing Functional Systems.
Cotelle Y, Chuard N, Lascano S, Lebrun V, Wehlauch R, Bohni N, Lörcher S, Postupalenko V, Reddy ST, Meier W, Palivan CG, Gademann K, Ward TR, Matile S. Cotelle Y, et al. Among authors: meier w. Chimia (Aarau). 2016;70(6):418-23. doi: 10.2533/chimia.2016.418. Chimia (Aarau). 2016. PMID: 27363370 Free article. Review.
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Shirinkin V, Selle F, Fielding A, Lowe ES, McMurtry EL, Spencer S, Rowe P, Mann H, Parry D, Ledermann J. Friedlander M, et al. Among authors: meier w. Br J Cancer. 2018 Oct;119(9):1075-1085. doi: 10.1038/s41416-018-0271-y. Epub 2018 Oct 24. Br J Cancer. 2018. PMID: 30353045 Free PMC article. Clinical Trial.
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
Pfisterer J, Joly F, Kristensen G, Rau J, Mahner S, Pautier P, El-Balat A, Kurtz JE, Canzler U, Sehouli J, Heubner ML, Hartkopf AD, Baumann K, Hasenburg A, Hanker LC, Belau A, Schmalfeldt B, Denschlag D, Park-Simon TW, Selle F, Jackisch C, Burges A, Lück HJ, Emons G, Meier W, Gropp-Meier M, Schröder W, de Gregorio N, Hilpert F, Harter P. Pfisterer J, et al. Among authors: meier w. J Clin Oncol. 2023 Feb 1;41(4):893-902. doi: 10.1200/JCO.22.01010. Epub 2022 Nov 4. J Clin Oncol. 2023. PMID: 36332161 Clinical Trial.
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U. Ledermann J, et al. Among authors: meier w. Lancet Oncol. 2014 Jul;15(8):852-61. doi: 10.1016/S1470-2045(14)70228-1. Epub 2014 May 31. Lancet Oncol. 2014. PMID: 24882434 Clinical Trial.
Synthetic Biology: Bottom-Up Assembly of Molecular Systems.
Hirschi S, Ward TR, Meier WP, Müller DJ, Fotiadis D. Hirschi S, et al. Among authors: meier wp. Chem Rev. 2022 Nov 9;122(21):16294-16328. doi: 10.1021/acs.chemrev.2c00339. Epub 2022 Sep 30. Chem Rev. 2022. PMID: 36179355 Review.
[Gynecologic emergencies].
Meier W, Gropp M. Meier W, et al. Internist (Berl). 2001 Nov;42(11):1470-5. doi: 10.1007/s001080170037. Internist (Berl). 2001. PMID: 11732100 Review. German. No abstract available.
539 results